Published in J Natl Cancer Inst on July 03, 2002
Coexpression analysis of human genes across many microarray data sets. Genome Res (2004) 9.38
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer (2010) 4.06
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 3.54
DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer (2012) 2.70
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14
Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) (2010) 1.80
Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol (2004) 1.79
BRCAness revisited. Nat Rev Cancer (2016) 1.38
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer (2011) 1.32
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30
Many accurate small-discriminatory feature subsets exist in microarray transcript data: biomarker discovery. BMC Bioinformatics (2005) 1.28
Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma (2008) 1.18
Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia (2011) 1.17
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev (2009) 1.16
PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 1.08
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol (2011) 1.06
BRCAness: finding the Achilles heel in ovarian cancer. Oncologist (2012) 1.05
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics (2004) 1.05
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer (2013) 1.03
Deubiquitylating enzymes and DNA damage response pathways. Cell Biochem Biophys (2013) 1.03
Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures. J Natl Cancer Inst (2002) 1.02
Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery. Semin Cancer Biol (2012) 1.01
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res (2010) 1.01
Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer (2009) 0.94
PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. Hum Pathol (2009) 0.92
Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol (2003) 0.92
Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells. Int J Biol Sci (2007) 0.91
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer (2005) 0.89
Interferons and the Immunogenic Effects of Cancer Therapy. Trends Immunol (2015) 0.84
Association of BRCA1 with the inactive X chromosome and XIST RNA. Philos Trans R Soc Lond B Biol Sci (2004) 0.83
Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients. Hered Cancer Clin Pract (2016) 0.81
BRCA1-mediated repression of select X chromosome genes. J Transl Med (2004) 0.81
Use of gene expression profiles of peripheral blood lymphocytes to distinguish BRCA1 mutation carriers in high risk breast cancer families. Cancer Inform (2009) 0.81
Re: Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 0.80
Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report. Hered Cancer Clin Pract (2006) 0.80
BRCA1 modulates the expression of hnRNPA2B1 and KHSRP. Cell Cycle (2010) 0.80
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. BMC Cancer (2010) 0.80
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia (2010) 0.79
How to improve postgenomic knowledge discovery using imputation. EURASIP J Bioinform Syst Biol (2009) 0.78
Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells. J Pathol (2014) 0.78
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol (2016) 0.77
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study. Cell Cycle (2015) 0.76
Molecular tumor profiling: translating genomic insights into clinical advances. Genome Biol (2004) 0.76
Study of the influence of the ph of water in the initiation of digestive tract injury in cadmium poisoning in rats. Toxicol Rep (2015) 0.75
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
International network of cancer genome projects. Nature (2010) 20.35
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Mapping human genetic diversity in Asia. Science (2009) 7.40
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet (2003) 5.99
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol (2006) 4.93
Evaluation of the Infinium Methylation 450K technology. Epigenomics (2011) 4.90
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res (2009) 4.47
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Accidental hypothermia. N Engl J Med (2012) 4.01
Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res (2008) 3.76
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells (2005) 3.16
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol (2004) 2.91
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol (2002) 2.80
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 2.72
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet (2010) 2.62
Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol (2005) 2.51
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50
Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res (2004) 2.47
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 2.34
Regulation of estrogen receptor-mediated long range transcription via evolutionarily conserved distal response elements. J Biol Chem (2008) 2.34
Transcriptome analysis of zebrafish embryogenesis using microarrays. PLoS Genet (2005) 2.32
Identification of cell cycle-regulated genes in fission yeast. Mol Biol Cell (2004) 2.29
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res (2008) 2.16
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res (2002) 2.16
Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A (2002) 2.15
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res (2003) 2.09
Early B cell factor 1 regulates B cell gene networks by activation, repression, and transcription- independent poising of chromatin. Immunity (2010) 2.08
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A (2005) 2.07
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol Syst Biol (2010) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res (2006) 2.02
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol (2009) 1.93
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86
DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81
Implication of snoRNA U50 in human breast cancer. J Genet Genomics (2009) 1.80
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res (2012) 1.77
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol (2003) 1.74
HER2-positive circulating tumor cells in breast cancer. PLoS One (2011) 1.73
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One (2011) 1.72
Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics (2008) 1.71
p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem (2004) 1.70
Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn (2002) 1.67
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res (2011) 1.67
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res (2012) 1.67
Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol (2005) 1.64
5' Long serial analysis of gene expression (LongSAGE) and 3' LongSAGE for transcriptome characterization and genome annotation. Proc Natl Acad Sci U S A (2004) 1.64
Comparison of avalanche survival patterns in Canada and Switzerland. CMAJ (2011) 1.62
Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol (2005) 1.62
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol (2007) 1.60
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol (2008) 1.57
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res (2004) 1.57
The Archon Genomics X PRIZE for whole human genome sequencing. Nat Genet (2010) 1.56
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res (2003) 1.56